ArticleVirus research2026
Kinetics of neutralizing and binding antibody responses following Zika virus infection during pregnancy: A nested analysis of participants from the microcephaly epidemic research group (MERG) and Zika in infants and pregnancy (ZIP) cohorts.
Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ZIKV infection during pregnancy can result in Congenital Zika Syndrome (CZS) in the newborn. Nevertheless, diagnosing ZIKV infection during pregnancy remains challenging, and the kinetics of the serological response to acute infection remains insufficiently reported in the literature. Using samples collected longitudinally from two cohorts of pregnant women in Brazil, this study aims to estimate the timeframe to reach anti-ZIKV immunoglobulin (IgM) negativity. Additionally, it seeks to describe the positivity of IgM, IgG3, and neutralizing antibodies based on the interval between symptom onset and testing in symptomatic pregnant women. In the cohort of pregnant women who tested ZIKV IgM-positive, the probability of IgM seroreversion after the initial detection. was 40% by 3 months, 75% by 6 months, and 85% by 12 months. Moreover, we observed a decreasing trend in the percentage of ZIKV-positive women with detectable ZIKV-specific IgM antibodies over the 12 months after infection, peaking at 8.1% 1 to 2-months after symptom onset and declining to 1.1% by 4 to 5-months after symptom onset. In contrast, IgG3 and neutralizing antibody detection remained stable over the observation period, with approximately <6% and 50% remaining detectable, respectively. This study adds to the body of evidence on the behavior of the antibody responses in a population of women infected with ZIKV during pregnancy. The findings advance understanding of the probability of seroconversion and seroreversion using different immune markers in ZIKV-infected pregnant women, and have the potential to improve the design of maternal screening and surveillance strategies for ZIKV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.